Serotype distribution of Streptococcus pneumoniae and pneumococcal vaccine coverage in adults in Turkey between 2015 and 2018

Basit Öğe Kaydı
dc.authoridAy Altintop, Yasemin/0000-0003-2410-208X
dc.authoridHascelik, Gulsen/0000-0002-1773-6167
dc.authoridGurler, Nezahat/0000-0002-1134-658X
dc.authoridAydemir, Sabire Sohret/0000-0001-8354-9100
dc.authoridBayramoglu, Gulcin/0000-0002-6103-3127
dc.authoridAydin, Faruk/0000-0002-0139-908X
dc.authoridGulay, Zeynep/0000-0002-4135-9154
dc.authorscopusid7006149773
dc.authorscopusid6603714045
dc.authorscopusid6603856635
dc.authorscopusid24780816000
dc.authorscopusid7003628472
dc.authorscopusid6603761998
dc.authorscopusid58037230100
dc.authorwosidAy Altintop, Yasemin/HIZ-8041-2022
dc.contributor.authorHascelik, Gulsen
dc.contributor.authorSoyletir, Guner
dc.contributor.authorGulay, Zeynep
dc.contributor.authorSancak, Banu
dc.contributor.authorYaman, Akgun
dc.contributor.authorGurler, Nezahat
dc.contributor.authorAydemir, Sabire Sohret
dc.date.accessioned2024-08-25T18:36:32Z
dc.date.available2024-08-25T18:36:32Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: To evaluate the serotype distribution and antibiotic resistance in pneumococcal infections in adults and to provide a perspective regarding serotype coverage of both current and future pneumococcal vaccines. Patients and methods: This passive surveillance study was conducted with the Streptococcus pneumoniae strains isolated from the specimens of patients with pneumonia (materials isolated from bronchoalveolar lavage), bacteraemia, meningitis, pleuritis and peritonitis between 2015 and 2018. Serogrouping and serotyping were performed by latex particle agglutination and by conventional Quellung reaction using commercial type-specific antisera, respectively. The strains were analysed for penicillin, cefotaxime, erythromycin and moxifloxacin susceptibilities by E-test. Results: In the whole study group (410 samples from adults aged >= 18 years), the most frequent serotypes were 3 (14.1%), 19 F (12%) and 1 (9.3%). The vaccine coverage for PCV13, PCV15, PCV20 and PPV23 was 63.9%, 66.6%, 74.1% and 75.9%, respectively, in all isolates. Penicillin non-susceptibility in invasive pneumococcal disease (IPD) was 70.8% and 57.1% in the patients aged <65 and >= 65 years, respectively. About 21.1% and 4.3% of the patients with and without IPD had cefotaxime resistance. Non-susceptibility to erythromycin and moxifloxacin was 38.2% and 1.2%, respectively. Conclusions: The results revealed that novel PCV vaccines may provide improved coverage as compared with the currently available vaccine, PCV13. The significant antibiotic resistance rates imply the need to extend the serotype coverage of the vaccines. Continuing the surveillance in pneumococcal diseases is critical to explore the serotype distribution and incidence changes of IPD cases in the population and to inform policy makers to make necessary improvements in the national immunization programmes.en_US
dc.identifier.doi10.1080/07853890.2022.2160877
dc.identifier.endpage275en_US
dc.identifier.issn0785-3890
dc.identifier.issn1365-2060
dc.identifier.issue1en_US
dc.identifier.pmid36579976en_US
dc.identifier.scopus2-s2.0-85145242334en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage266en_US
dc.identifier.urihttps://doi.org/10.1080/07853890.2022.2160877
dc.identifier.urihttps://hdl.handle.net/11454/100671
dc.identifier.volume55en_US
dc.identifier.wosWOS:000904928200001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofAnnals of Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.subjectStreptococcus pneumoniaeen_US
dc.subjectserotypeen_US
dc.subjectsurveillanceen_US
dc.subjectvaccine coverageen_US
dc.subjectantibiotic susceptibilityen_US
dc.subjectPolysaccharide Conjugate Vaccineen_US
dc.subjectAntimicrobial Resistanceen_US
dc.subjectDiseaseen_US
dc.subject13-Valenten_US
dc.subjectChildrenen_US
dc.subjectBurdenen_US
dc.subjectImpacten_US
dc.titleSerotype distribution of Streptococcus pneumoniae and pneumococcal vaccine coverage in adults in Turkey between 2015 and 2018en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu